Reference: June 2025 | Issue 6 | Vol 11 | Page 42
The positive impact sport has on health is well recognised. However, each Spring the number of sport injuries arriving into the primary care clinic or on the physiotherapist’s table can be prevented.
The incidence of injury in sports has increased due to a rise in participation, poor injury prevention strategies, and faulty or inadequate training. In fact, the prevalence of injury was highlighted in a 12-month, prospective study carried out on 324 Irish athletes involved at a high level in contact, noncontact, or explosive sports.
A significant portion of athletes (40 per cent) suffer an injury within a year. The average athlete sustains around 1.17 acute and 0.93 overuse injuries a year, leading to an average of 52 days of lost time due to injury.
The most common injuries include lumbar muscle strains, ankle sprains, and bone fractures. Not surprisingly contact sports tend to have higher acute injury rates compared to non-contact sports. However, key factors associated with higher injury rates include increased training hours, inadequate facilities, and inappropriate training loads.
The younger athlete is at greater risk mainly due to limited knowledge on how to avoid injury. For the professional athlete, these factors can inadvertently shorten their career and have significant implications for their quality of life.
Most individual musculoskeletal injuries (MSK) in sports are a consequence of chronic misuse or overuse. Many of these problems can be treated conservatively with rest, non-steroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and rehabilitation. Unfortunately, some individuals do not respond well to rehabilitation and formal intervention.
Pathology of MSK injury
The underlying pathology in persistent cases of MSK injury can be related to irreversible microstructural changes in the connective tissue that has failed to recover and adapt to rehabilitation. Typically, recovering from any injury is regarded as a three-phase process, outlined in Table 1. The tendons and the enthesis are where biomechanical stress is higher at any given point in a practising athlete, the muscle, cartilage, and bone are also affected under chronic stress.
These problems do not have an effective treatment modality and this is the grey area where orthopaedic surgeons and sports physicians are trying to employ biological therapy to hasten the repair and bring about recovery.
In regenerative medicine, which is a growing therapy globally, procedures like platelet-rich plasma (PRP) injections have shown promise. From a clinical perspective, regenerative sports medicine focuses on injuries related to sports activities and ageing, involving various components of the musculoskeletal system such as menisci, ligaments, tendons, cartilage, and bones. PRP has shown its utility as an interventional therapy for sports injuries in specific cases.
Historically
The concept of using the body’s own inherent healing mechanism to assist in the repair, and to potentially replace or restore damaged tissue through the use of autologous or allogenic biologics, has always been considered a possibility. PRP began as early as the 1980s in the clinical setting, when it was found to be effective in reducing blood loss during cardiac surgery. Its effect on bone was then examined in the field of dentistry for its regenerative properties on bone maturation and formation.
In time, its use in musculoskeletal medicine has grown, and a role in tendon and tissue healing has been heavily investigated. Over the last 10 years, there has been an increase in the use of PRP among medical clinicians, especially for its potential in treating tendinopathy and degenerative cellular diseases.
Within the speciality of pain management the use of regenerative medicine is a relatively new treatment option. PRP contains numerous growth factors and cytokines that potentially offer an alternative treatment modality to assist in the healing of multiple musculoskeletal issues. The use of PRP is expanding exponentially, creating new frontiers for the treatment of musculoskeletal and spinal pain.
One reason for the growth in interest in PRP is because, according to World Anti-doping Agency (WADA) regulations, PRP is not prohibited. Although individual growth factors are still prohibited when given separately as purified substances.
TENDON HEALING PHASES | CELLULAR MECHANISMS | REHABILITATION PHASES | CONSIDERATIONS | COMPONENTS |
Phase I Inflammatory phase (48–72 hours) |
Debris removed from damaged tissue Cytokines and growth factors recruited |
Tissue protection (0–3 days) |
Reduction of load to the involved joint Avoid NSAIDs |
Adequate rest Initiate assisted range of motion Other activities as tolerated |
Phase II Proliferative phase (48 hours to 6 weeks) |
Proteolytic degradation Chemotaxis Fibroblastic activity |
Early tissue healing (4 days to 6 weeks) |
Progressive loading of the involved joint Avoid cryotherapy Avoid NSAIDs Avoid eccentric training |
Gentle prolonged stretches to dynamic stretches Isometric exercises Strengthening of the adjacent kinetic chain |
Phase III Maturation phase (>6 weeks) |
Accumulation of type I collagen Remodelling |
Collagen strengthening (6 weeks to 3 months) |
Closed kinetic chain exercises Plyometric and proprioceptive training Eccentric strengthening Sports specific drills RTS after three months if pain scale <3/10 |
TABLE 1: Phases of tendon healing and corresponding phases of rehabilitation: Reference Indian Journal of Orthopaedics (2021) 55:484-491
Why does PRP work?
In the early phase of any injury the inflammatory phase predominates. Ice, rest, activity modification, and anti-inflammatory medications are generally included in the current mode of management. Many injuries settle but in some cases local steroid injections are required. While steroids are the gold standard to reduce inflammation, they do little to directly promote the healing phase. Occasionally even steroids fail to resolve the symptoms leaving the individuals with a long uphill battle to recovery.
This is fundamentally where PRP therapy has an important role. PRP therapy can increase the rate of musculoskeletal healing by stimulating angiogenesis, cell proliferation, and chemotaxis. It has been demonstrated that PRP promotes healing in cases of tendinous and ligamentous injury and muscular strain. It has been utilised to shorten the recovery period and has helped improve the recovery time of athletes.
PRP seeks to recruit and enhance the body’s own inherent healing mechanism to assist in the repair, and to potentially replace or restore damaged tissue through the use of autologous or allogenic biologics
How is PRP prepared?
Generally, the preparation of PRP involves obtaining autologous whole blood from the patient, followed by a centrifugation process to separate plasma from red blood cells and leukocytes. The method of isolation plays a role in the final concentration of platelets and leukocytes in the PRP preparation. What was once a complex ‘event’ has been simplified into a three-step process.
1. Withdraw a blood sample in a specific collecting tube.
2. Centrifuge the sample to separate the plasma, which is rich in several growth factors.
3. Reinject the product at the injury site. This is best undertaken using image guidance such as ultrasound or fluoroscopy to improve accuracy.
This preparation process, and the injection of the PRP, can be completed in a matter of minutes using simple clinical equipment, allowing safe delivery to the effected site. Ultrasound guidance is preferrable to increase accuracy and improve treatment outcome.
What does PRP contain?
Platelets, which are one of the main components in PRP, help mediate the release of several growth factors that are essential in the healing process. These include platelet-derived growth factor (PDGF), transforming growth factor (TGF-β), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor (IGF). These growth factors are essential for the three phases of healing.
The proposed healing benefit of PRP is that it allows for the patient’s own blood to provide a high concentration of growth factors at injury sites that have limited healing capacity due to blood supply. This matrix serves as scaffold for sustained release of growth factors that drive chemotaxis and angiogenesis.
There are several basic science studies to support the use of PRP for tendon and ligament healing in the in vivo setting. PRP has been shown to:
a) Induce tendon cell proliferation along with induction of angiogenic factors.
b) Have anabolic effects on tendon cells by increasing the total collagen synthesis in tenocytes. Collagen type I seems to be promoted by PRP and may help limit the development in fibrotic tissue. There is an important ratio between different types of collagen and a balance seems necessary to avoid increase fibrosis and reduced strength of a tendon.
What is the clinical evidence to support PRP?
The evidence in the literature reflects greater use of the technique globally.
a) Lateral epicondylitis
Also known as tennis elbow, PRP has shown very favourable results compared to traditional steroid injection. In a meta-analysis of randomised controlled trials examining the use of PRP, it was reported that PRP was significantly more effective at reducing pain intensity compared to various controls in both short-term (<6.5 months) and long-term (>1 year) follow-up periods.
In 2017, a study was undertaken to compare outcomes between a single PRP injection and surgery for patients suffering from lateral elbow tendinopathy. It appears that both can give at least similar pain relief in the first 12 months but after two years, arthroscopy was superior to PRP regarding long-term pain and functional outcomes. Nevertheless, for some individuals, an annual 15 minute bed-side procedure may be the preferred option.
b) Rotator cuff tendinopathy
The use of PRP in rotator cuff pathology has come with mixed results in the literature. Early studies on augmenting rotator cuff repair with PRP have been inconsistent with regard to clinical outcomes. A more recent meta-analysis by Hurley et al. examined over 18 randomised controlled studies comparing PRP to arthroscopic repair alone. Their study included over 1,147 patients and it found that PRP had significantly decreased rates of incomplete tendon healing for small-medium and medium-complete tears. They also found a significant decrease in visual analog scores (VAS pain score) at 30 days and final follow-up compared to the control group.
c) Patellar tendinopathy
Patellar tendinopathy, otherwise known as jumper’s knee, is characterised by chronic pain as a result of overuse. The clinical evidence suggests PRP can improve pain and function, with up to 22-81 per cent of patients able to return to their pre-symptom level of activity.
The number of PRP injections has also been shown to have an effect on the outcome of the treatment, with two injections found to improve outcomes significantly more than a singular injection.
d) Achilles tendinopathy
Due to the increased competitiveness , an aging population and rising obesity rates the incidence of Achilles tendon rapture is on the rise. The majority of severe Achilles tendon injuries occur as a result of sports activities. Professional athletes are more prone to Achilles tendon injury. Approximately 30-50 per cent of sports-related injuries involve tendon issue. Sports such as jogging, badminton, squash, or training in subzero weather put individuals at higher risk of an Achilles tendon injury.
The Achilles tendon is a conjoined structure composed of the tendinous regions of the superficial posterior compartment musculature. The tendon resists forces up to 12 times body weight during exercise and it is amongst the strongest in the body. Despite its robust structure, it is also amongst the most frequently ruptured tendons in the lower extremity and accounts for 20 per cent of major tendon injuries. Due to its relative non-invasiveness and minimal risk, PRP injections are being investigated with hopes of improving tendinopathy outcomes. Unfortunately, the initial results are not very encouraging.
e) Ulnar collateral ligament injury
Injury to the medial ulnar collateral ligament (MUCL) occurs as a result of extraneous valgus loads and it is common in overhead-throwing athletes. A fully torn ligament or one that has not responded favourably to conservative treatment will be treated surgically; however, success rates have varied from 83 to 90 per cent for a return to the sports field by 9-12 months post-surgery.
A case study by Hoffman et al detailed the outcome of an MUCL reconstruction in a 25-year-old professional baseball pitcher that was augmented with a dermal allograft reconstituted in PRP and mesenchymal stem cells. The authors found that their patient was able to return to pitching by four months post-op.
Despite various case reports, there are no available randomised controlled trials examining the effectiveness of PRP on MUCL and it is still unclear whether PRP expedites return to play in the conservative management of UCL injuries.
f) Anterior cruciate ligament
The anterior cruciate ligament (ACL) is vital to the stability of the knee and its rupture requires surgical intervention to restore this functionality. A systematic review by Figueroa et al regarding ACL repair, with the aid of PRP, showed variable results in terms of clinical outcomes, bone tunnel healing/widening, and graft maturation.
The use of PRP may show more promise in partial tears. A systematic review by Di Matteo et al included two studies of PRP used for partial ACL tears, which showed that between 70 and 84 per cent of patients return to their previous level of activity without surgery. Initial research regarding the use of PRP to treat ACL injuries shows promise in terms of its ability to help induce cell growth for various grafts; however, there is not sufficient research to conclude the best composition of PRP injections to induce the maximal amount of healing.
g) Other options
With the ease of preparation, improved ultrasound accessibility, and a growing awareness in the medical community, the probability is that different tendons and ligaments are going to be injected. For refractory cases such as gluteal tendonitis, ankle ligament, and hand injury, the therapy will continue to open up simple treatment options for more individuals.
The initial feedback is very encouraging both in terms of pain reduction and improved functional capacity. Capturing this data in a form that can be shared to advance the treatment is an important challenge.
While regenerative PRP management can be provided independently, it should be provided in conjunction with other modalities of treatment including a structured exercise programme, physical therapy, behavioural therapy, and appropriate conventional medical therapy as necessary. Appropriate precautions should be taken into consideration and followed prior to performing biologic therapy.
In conclusion, PRP has shown great promise as a treatment modality for sports injuries. Its regenerative properties and ability to promote tissue healing have made it a very valuable option for conditions commonly encountered in sports, such as tendon and ligament injuries.
PRP has demonstrated effectiveness in mending specific sports-related conditions like tennis elbow, jumper’s knee, and runner’s knee. Further research is needed to optimise PRP protocols and understand the mechanism of action in sports injury. PRP holds significant potential for enhancing recovery and rehabilitation of athletes, ultimately contributing to improved outcomes in the field of sports medicine. l
Disclosure
Prof Dominic Hegarty, (BSc, BMedSc,MB, MSc (Pain management), PhD FCARSCI, FFPMCAI, FIPP) is a Consultant in Pain Management at the Mater Private Hospital, Cork and Clinical Director of Pain Relief Ireland. Prof Hegarty does not receive reimbursement from any specific company to use or promote the technique or products mentioned in this article.
References
- American Society of Interventional Pain Physicians (ASIPP): Responsible, safe, and effective use of biologics in the management of low back pain. ASIPP guidelines pain physician 2019; 22: S1-S74 ISSN 1533-3159.
- WADA regulations www.usada.org/spirit-of-sport/orthobiologics-athletes-need-know-prp/.
- Andriolo L, Sante Altamura SA, et al. Nonsurgical treatments of patellar tendinopathy: Multiple injections of platelet-rich plasma are a suitable option: A systematic review and meta-analysis. Am J Sports Med. 2018;363546518759674 https: doi.org/10.1177/ 0363546518759674. They conducted a systematic analysis in 2017 and found PRP to be a suitable option for chronic tendinopathy and also demonstrated that number of injections along with incorporation of physical therapy were important in treatment.
- Anjanavanna MM, Perumal S, Alwar T, et al. Platelet‑rich plasma (PRP) injection in sports injuries. Indian Journal of Orthopaedics (2021) 55:484-491.
- Anitua E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14(4):529-35.
- Anitua E, Andia I, Sanchez M, et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res. 2005;23:281-6.
- Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585-601.
- Benjamin M, Toumi H, Ralphs JR, et al. Where tendons and ligaments meet bone attachment sites (‘entheses’) in relation to exercise and/or mechanical load. J Anat. 2006;208(4):471-90.
- Chen L, Dong SW, Tao X, et al. Autologous platelet-rich clot releasate stimulates proliferation and inhibits differentiation of adult rat tendon stem cells towards nontenocyte lineages. J Int Med Res. 2012;40(4):1399-409.
- Chen X, Jones IA, Park C, et al. The efficacy of platelet- rich plasma on tendon and ligament healing: A systematic review and meta-analysis with bias assessment. Am J Sports Med. 2018 Jul;46(8):2020–32.
- Clark NJ, Desai VS, Dines JD, et al. Nonreconstruction options for treating medial ulnar collateral ligament injuries of the elbow in overhead athletes. Curr Rev Musculoskelet Med. 2018 Mar;11(1):48-54.
- Dayton P. Anatomic, vascular, and mechanical overview of the Achilles tendon. Clin Podiatr Med Surg. 2017;34(2):107-13.
- DelRossi AJ, Cernaianu AC, Vertrees RA, et al. Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;100(2):281-6.
- Di Matteo B and Kon GFE. Platelet-rich plasma: Evidence for the treatment of patellar and Achilles tendinopathy – a systematic review. Musculoskelet Surg. 2015;99(1):1-9.
- Di Matteo B, Loibl M, Andriolo L, et al. Biologic agents for anterior cruciate ligament healing: A systematic review. World J of Orthop. 2016;7(9):592-603.
- Ferrari M, Zia S, Valbonesi M, et al. A new technique for haemodilution, preparation of autologous platelet-rich plasma, and intraoperative blood salvage in cardiac surgery. Int J Artif Organs. 1987;10(1):47-50.
- Figueroa D, Figueroa F, Calvo R, et al. Platelet-rich plasma use in anterior cruciate ligament surgery: Systematic review of the literature. J of Arth and Rel Surg. 2015;31(5):981-8.
- Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich plasma: From basic science to clinical applications. Am J Sports Med. 2009;37:2259-72.
- Geaney LE, Arciero RA, DeBarradino TM, et al. The effects of platelet-rich plasma on tendon and ligament: Basic science and clinical application. Oper Tech Sports Med. 2011;19(3):160-4.
- Gosens T, Den Oudsten BL, et al. Pain and activity levels before and after platelet-rich plasma injection treatment of patellar tendinopathy: A prospective cohort study and the influence of previous treatments. Int Orthop. 2012;36(9):1941-6.
- Hak A, Rajaratnam K, Ayeni OR, et al. A double-blinded placebo randomised controlled trial evaluating short-term efficacy of platelet-rich plasma in reducing postoperative pain after arthroscopic rotator cuff repair: A pilot study. Sports Health. 2015;7(1):58-66.
- Hurley ET, Lim Fat D, Moran CJ, et al. The efficacy of platelet-rich plasma and platelet-rich fibrin in arthroscopic rotator cuff repair: A meta-analysis of randomised controlled trials. Am J Sports Med. 2018; https://doi.org/10.1177/03635465177513997.
This metanalysis encompassed over 18 randomised controlled trials with more than 1,147 patients and was recently published this year. Their findings found significant improvement with pain and healing after rotator cuff repair using PRP. - Kia C, Baldino J, Bell R, et al. Platelet-rich plasma: Review of current literature on its use for tendon and ligament pathology. Current Reviews in Musculoskeletal Medicine (2018) 11:566-572.
- Liddle AD and Rodríguez-Merchán C. Platelet-rich plasma in the treatment of patellar tendinopathy: A systematic review. Am J Sports Med. 2015;Oct: 43(10):2583-90.
- Madry H, Kohn D, Cucchiarini M. Direct FGF-2 gene transfer via recombinant adeno-associated virus vectors stimulates cell proliferation, collagen production, and the repair of experimental lesions in the human ACL. Am J Sports Med. 2013;41:194-202.
- Malanga GA, Goldin M. PRP: Review of the current evidence of the current evidence of musculoskeletal conditions. Curr Phys Med Rehab. 2014;2(1):1-15.
- Marui T, Niyibizi C, Georgescu HI, et al. Effect of growth factors on matrix synthesis by ligament fibroblasts. J Orthop Res. 1997;15:18-23.
- Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85(6):638-46.
- Mazzocca AD, McCarthy MB, Chowaniec DM, et al. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012;94:308-16.
- McCarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilised platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res. 2009;27(8):1033-42.
- Merolla G, Dellabiancia F, Ricci A, et al. Arthroscopic debridement versus platelet-rich plasma injection: A prospective, randomised, comparative study of chronic lateral epicondylitis with a nearly two-year follow-up. Arthrosc J Arthrosc Relat Surg. 2017 Jul;33(7):1320-9.
- Nguyen RT, Borg-Stein J, McInnis K. Applications of platelet-rich plasma in musculoskeletal and sports medicine: An evidence-based approach. PMR. 2011;3(3):226-50.
- Patil P, Jadhav M, Suvvari TK, et al. Therapeutic uses of platelet-rich plasma (PRP) in sport injuries – a narrative review. JOREP 3 (2024) 100287.
- Podesta L, Crow SA, Volkmer D, et al. Treatment of partial ulnar collateral ligament tears in the elbow with platelet-rich plasma. Am J Sports Med. 2013;41(7):1689-94.
- Scherer SS, Tobalem M, Vigato E, et al. Nonactivated versus thrombin-activated platelets on wound healing and fibroblast-myofibroblast differentiation in vivo and in vitro. Plas Reconstr Surg. 2012;129(1):46e-54e.
- Unlu M, Kivrak A, Kayaalp ME, et al. Peritendinous injection of platelet-rich plasma to treat tendinopathy: A retrospective review. Acta Orthopaedica et Traumatologica Turcica 51 (2017) 482e487.
- Zhang J, Wang JH. Platelet-rich plasma releasate promotes differentiation of tendon stem cells into active tenocytes. AJSM. 2010;38(12):2477-86.
- Zhao JG, Zhao L, Jiang YX, et al. Platelet-rich plasma in arthroscopic rotator cuff repair: A meta-analysis of randomised, controlled trials. Arthroscopy. 2015 Jan;31(1):125-35.
- Zhou Y, Wang J. PRP treatment efficacy for tendinopathy: A review of basic science studies. Biomed Res Int. 2016;2016:1-8. https:// doi.org/10.1155/2016/9103792.
